Results 61 to 70 of about 5,988,794 (310)

Impact of students’ self-regulation and mindfulness on academic self-efficacy; the mediation effect of mental well-being

open access: yesCogent Education
This study explored how academic self-efficacy was affected by self-regulation, mindfulness and their indirect impacts through mental well-being among higher education students in the Maldives.
Mariyam Shareefa   +4 more
doaj   +1 more source

Association Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko   +19 more
wiley   +1 more source

Confidence intervals and P-values for meta-analysis with publication bias [PDF]

open access: yes, 2006
We study publication bias in meta-analysis by supposing there is a population (y, sigma) of studies which give treatment effect estimates y - N(theta, sigma(2)). A selection function describes the probability that each study is selected for review.
John B. Copas   +5 more
core   +1 more source

Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse.
Elizabeth Sokol   +6 more
wiley   +1 more source

Nanoparticle-mediated mRNA delivery for cancer, autoimmunity, and genetic diseases: a rapid review

open access: yesFrontiers in Drug Delivery
IntroductionMessenger RNA (mRNA) therapeutics have advanced from experimental platforms to clinical application, driven largely by the success of lipid nanoparticle (LNP)-based COVID-19 vaccines.
Okechukwu Paul-Chima Ugwu   +5 more
doaj   +1 more source

PUBLICATION FUND COMMITTEE MINUTE BOOKS [PDF]

open access: yes, 1945
This record was harvested from a previous catalogue system and will be withdrawn in 2025. Information in this record may be superseded or incomplete.
University Of Melbourne. Publication Fund Committee
core  

For the public, with the public, by the public

open access: yes, 2012
University museums have played a significant role in the development of science and engineering knowledge for a long time. The first professorship of technology at Edinburgh University was synonymous with the position of curator of the university’s newly founded Industrial Museum.
openaire   +1 more source

Survival by Race and Ethnicity in Children and Adolescents/Young Adults With Relapsed/Refractory Hodgkin Lymphoma: A Pooled Analysis of Children's Oncology Group Trials

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Despite 5‐year survival rates of over 90% among children and adolescents/young adults (CAYAs) with classic Hodgkin lymphoma (cHL), 15%–20% relapse after frontline therapy. Prior analysis of frontline Children's Oncology Group (COG) clinical trials demonstrated that, despite similar rates of relapse, non‐Hispanic Black (NHB) and ...
Mallorie B. Heneghan   +14 more
wiley   +1 more source

In Their Own Words publication [PDF]

open access: yes, 2012
This publication synthesises key findings from the the Jisc Learner Experiences studies, drawing together themes from the Phase 1 reports1 and the 5 Learner Voice2 video case studies.

core  

Publication Services [PDF]

open access: yes, 2019
Some information on the publication services offered by the library and recommendations for ...
Köhler, Martin
core   +1 more source

Home - About - Disclaimer - Privacy